Dyne Therapeutics Names Editas Medicine's Lucera as CFO
Editas Medicine: Amy Parison to Succeed Lucera
Press Release: Editas Medicine Announces Chief Financial Officer Transition
Express News | Editas Medicine Announces Chief Financial Officer Transition
JonesTrading Maintains Editas Medicine(EDIT.US) With Hold Rating
Cautious Hold Rating on Editas Medicine Amid Early Development Stage and Long-Term Milestones
BofA Securities Maintains Editas Medicine(EDIT.US) With Sell Rating, Maintains Target Price $1
A Quick Look at Today's Ratings for Editas Medicine(EDIT.US), With a Forecast Between $1 to $5
Sell Rating for Editas Medicine Amid Strategic Shift and Competitive Pressures
Buy Rating for Editas Medicine Driven by Promising Preclinical Advances and Strong Financial Position
Editas Medicine (EDIT) Gets a Buy From Evercore ISI
Editas Medicine Inc.'s Stock Volatility: Key Risks and Investor Considerations
Analysts' Top Healthcare Picks: Editas Medicine (EDIT), Viking Therapeutics (VKTX)
Editas Q4 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down
RBC Capital Maintains Editas Medicine(EDIT.US) With Hold Rating, Maintains Target Price $4
Analysts Offer Insights on Healthcare Companies: Editas Medicine (EDIT), Elanco Animal Health (ELAN) and Verona Pharma (VRNA)
Wells Fargo Maintains Editas Medicine(EDIT.US) With Hold Rating, Maintains Target Price $3
Barclays Maintains Editas Medicine(EDIT.US) With Hold Rating, Maintains Target Price $3
Editas Medicine: Balancing Financial Stability and Strategic Uncertainties With a Hold Rating
Editas Medicine (EDIT) Reports Q4 Loss, Misses Revenue Estimates